Elsevier

Brain Research

Volume 631, Issue 2, 24 December 1993, Pages 191-202
Brain Research

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

https://doi.org/10.1016/0006-8993(93)91535-ZGet rights and content

Abstract

Risperidone (Risperdal) is a novel antipsychotic drug, with beneficial effects on both positive and negative symptoms of schizophrenia, and with a low incidence of extrapyramidal side effects (EPS). These particular properties have been attributed to the predominant and very potent serotonin 5-HT2 receptor antagonism of the drug combined with less potent dopamine D2 antagonism. In order to provide data on the degree to which various central neurotransmitter receptors are occupied in vivo, we performed ex vivo receptor occupancy studies with risperidone in comparison with clozapine and haloperidol in rats and guinea pigs. Various types of receptors, to which the compounds were known to bind to in vitro, were investigated precisely using receptor autoradiography in sections of the same rat brain except for histamine H1 receptors that were measured in the guinea-pig cerebellum. Risperidone (2 h after s.c. treatment) occupied 5-HT2 receptors at very low doses (ED50 = 0.067mg/kg). Nearly full occupancy (80%) was achieved before H1, D2, α1 andα2 receptors became occupied (ED50 = 0.45, 0.66, 0.75and3.7mg/kg, respectively). Clozapine displayed occupancy of H1 andα1 receptors at low doses (ED50 = 0.15and0.58mg/kg, respectively) and of 5-HT2, 5-HT1C, D2, α2, cholinergic muscarinic and 5-HT1A receptors at higher dosesED50 = 1.3, 1.8, 9.0, 9.5, 11and15mg/kg, respectively). Haloperidol occupied D2 andα1 receptors at low doses (ED50 = 0.13and0.42mg/kg, respectively) and 5-HT2 receptors at a higher dose (ED50 = 2.6mg/kg). Occupancy of receptor types occurred with similar ED50-values in various brain areas, e.g. D2 receptors in striatum and mesolimbic areas. The ED50-values for the ex vivo measured occupancy of 5-HT2 and D2 receptors were in good agreement with ED50-values for functional effects putatively mediated by these central receptors. The dose-dependent occupancy of D2 receptors proceeded more gradually with risperidone (slope in the caudate-putamen: 0.85) than with clozapine (slope: 1.44) or haloperidol (slope: 1.51). It has previously been suggested that partial D2 receptor occupancy may suffice to control the positive symptoms of schizophrenia, whereas higher D2 receptor occupancy would induce extrapyramidal symptoms (EPS). The dose ratio for high (75%) vs. low (25%) D2 receptor occupancy in the caudate-putamen, was 37.3 for risperidone, 8.4 for clozapine, and 7.9 for haloperidol. It was also suggested that a strong 5-HT2 receptor blockade preceding a low occupancy of D2 receptors underlies the beneficial effects on the negative symptoms of schizophrenia and reduces incidence of EPS. At dosages inducing 25% D2 receptor occupancy in the caudate-putamen, risperidone (0.11 mg/kg) showed 60% occupancy of 5-HT2 receptors and less than 25% occupancy of the other receptors including H1 receptors. At 25% D2 receptor occupancy, clozapine (3.1 mg/kg) resulted in 65% occupancy of 5-HT2 receptors, but also in more than 80% occupancy ofα1 receptors and full occupancy of H1 receptors. At 25% D2 receptor occupancy, haloperidol (0.048 mg/kg) virtually did not interfere with other receptors. Our study provides evidence that risperidone shows an in vivo receptor occupancy profile in the rat brain that is compatible with the one that is apparently required for beneficial clinical effects, i.e. predominant 5-HT2 receptor occupancy concomitant with low D2 receptor occupancy; the gradual increase in D2 receptor occupancy with increasing dosages provides a wider therapeutic window before EPS-inducing high D2 receptor occupancy is reached.

Reference (40)

  • BaronB.M. et al.

    p-[125I]Iodoclonidine, a novel radiolabelled agonist for studying centralα2-adrenergic receptors

    Mol. Pharmacol.

    (1990)
  • BersaniG. et al.

    5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double blind with orphenadrine and placebo

    Clin. Neuropharmacol.

    (1990)
  • BorisonR.L. et al.

    Risperidone clinical safety and efficacy in schizophrenia

    Psychopharmacol. Bull.

    (1992)
  • ChouinardG. et al.

    A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenic patients

    J. Clin. Pharmacol.

    (1993)
  • CowardD.M. et al.

    Biochemical and behavioural properties of clozapine

    Psychopharmacology

    (1989)
  • CrowT.J. et al.

    The nucleus accumbens — possible site of antipsychotic action of neuroleptic drugs?

    Psychol. Med.

    (1977)
  • FardeL. et al.

    Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side-effects

    Arch. Gen. Psychiatry

    (1992)
  • FinneyD.J.

    Maximum likelihood estimation

  • GeldersY.G. et al.

    Pilot clinical investigation of risperidone in the treatment of psychotic patients

    Pharmacopsychiatry

    (1990)
  • GrohmannR. et al.

    Adverse effects of clozapine

    Psychopharmacology

    (1989)
  • Cited by (0)

    View full text